How could the FDA's review status of molgramostim affect the European Medicines Agency?
Savara's US drug review delay may influence EMA's European decision The ongoing review of Savara's molgramostim in the United States, which missed its goal date of November 22, 2026, provides context to the global regulatory assessment. The FDA and the European Medicines Agency actively coordinate on drug approval processes, sharing regulatory guidance. Since Savara's UK application was accepted under accelerated review, with the EMA committee decision expected in the first quarter of 2027, the status of the US review is a factor in the EMA's overall evaluation of the drug's global viability.
- Effect
- Mixed
- How direct
- Stated in the reporting
- When
- Within months
- The story
- Still developing
How it reaches European Medicines Agency
-
The FDA confirmed that the review of Savara Inc.'s inhaled drug, molgramostim, will not meet its goal date of November 22, 2026, and no new date has been set. The agency stated the review remains ongoing and did not issue a formal rejection letter. Separately, the FDA issued a rejection to Capricor Therapeutics for its cell therapy, deramiocel.
The full event1independent outlet -
The FDA and the European Medicines Agency actively coordinate on drug approval processes, sharing regulatory guidance and evaluating submissions globally. The status of the US review provides a key piece of information regarding the drug's global regulatory trajectory. The European Medicines Agency's committee decision regarding Savara's UK application is expected in the first quarter of 2027. The ongoing US review status is a factor in the EMA's assessment as it evaluates the drug's potential for market access.
1 report connects these two. Brind only summarizes; follow a link to read the reporting itself.
- techtimes.com 10 hours ago
-
highest regulatory authority on medicines in the European Union
Everything about European Medicines Agency
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- Savara's molgramostim review missed its goal date of November 22, 2026, but has not been rejected.techtimes.com
- The FDA and the European Medicines Agency actively coordinate on drug approval processes.techtimes.com
- The EMA committee decision for Savara's UK application is expected in the first quarter of 2027.techtimes.com
Why it matters
The EMA's role is crucial in establishing the regulatory framework for a rare disease treatment across the European Union. Since Savara's molgramostim is intended to be the first approved treatment for aPAP in the U.S. and Europe, the EMA's decision carries significant weight for patient access and the drug's commercial viability.
This situation highlights the complexity of global drug approval, where regulatory bodies like the FDA and EMA must coordinate while managing different timelines and data sets. The US delay, alongside the rejection of Capricor's application due to data integrity issues, contributes to the overall context of drug development risk in the market.
What we don't know yet
- Will the FDA issue a complete response letter or a new goal date for molgramostim?
- How will the EMA factor the US regulatory delay into its Q1 2027 decision?
What would change this answer
Who else could feel it
Other possible ripples from the same event.
- companyPossibleRegulatory uncertainty in rare disease drug development may increase risk for companies.
- Center for Biologics Evaluation and ResearchPossibleFDA's handling of biologics applications may shift CBER's operational focus
- United States of AmericaPossibleIncreased uncertainty over aPAP treatments could prolong reliance on invasive care in the US
Reporting
- techtimes.com10 hours ago
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.